{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:13:56Z","timestamp":1788902036173,"version":"build-2803163510"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"\n 68<\/jats:sup>\n Ga-FAPI PET\/CT has demonstrated higher sensitivity than\n 18<\/jats:sup>\n F-FDG PET\/CT in breast cancer, particularly in invasive lobular carcinoma. However, its role in treatment response assessment remains limited. We report a case of recurrent metastatic pleomorphic lobular breast cancer in which baseline\n 68<\/jats:sup>\n Ga-FAPI PET\/CT revealed extensive regional and distant disease underestimated by\n 18<\/jats:sup>\n F-FDG PET\/CT. Serial follow-up FAPI PET\/CT after initiation of olaparib demonstrated marked response with near complete resolution of disease, highlighting the potential utility of FAPI PET\/CT for response assessment in lobular breast cancer.\n <\/jats:p>","DOI":"10.1097\/rlu.0000000000006540","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:00:43Z","timestamp":1779127243000},"page":"e922-e923","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Beyond FDG"],"prefix":"10.1097","volume":"51","author":[{"given":"Khulood","family":"Al Riyami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asiya","family":"Al Busaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Ismaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharjeel","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s12149-021-01672-x","article-title":"Superiority of 68Ga-FAPI PET\/CT scan in detecting additional lesions compared to 18FDG PET\/CT scan in breast cancer","volume":"35","author":"Elboga","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/MNM.0000000000001880","article-title":"Enhancing precision in bone metastasis diagnosis for lobular breast cancer: reassessing the role of 18 F-FDG PET\/CT","volume":"45","author":"Usmani","year":"2024","journal-title":"Nucl Med Commun"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/ph16040521","article-title":"Head-to-head comparison between [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET\/CT Imaging in patients with breast cancer","volume":"16","author":"Ballal","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12149-023-01852-x","article-title":"What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature","volume":"37","author":"Evangelista","year":"2023","journal-title":"Ann Nucl Med"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.semnuclmed.2025.11.008","article-title":"Clinical utility of FAPI PET\/CT in diagnosis, staging, and response assessment of colorectal cancer","volume":"56","author":"Xie","year":"2026","journal-title":"Semin Nucl Med"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1007\/s00259-025-07271-6","article-title":"[18F]FAPI- 04 PET\/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment","volume":"52","author":"Li","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20260908","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/RLU.0000000000004744","article-title":"The role of 68 Ga-FAPI PET\/CT in breast cancer response assessment and follow-up","volume":"48","author":"Eshet","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MNM.0000000000001977","article-title":"The role of 68 Ga-FAPI PET\/CT imaging in gynecological cancers: an integrative review","volume":"46","author":"Usmani","year":"2025","journal-title":"Nucl Med Commun"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:00:37Z","timestamp":1788901237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006540"}},"subtitle":["Serial 68Ga-FAPI PET\/CT for Staging and Treatment Response Assessment in Metastatic Pleomorphic Lobular Breast Cancer"],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006540","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2026-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}